Nasdaq · Healthcare
Gossamer Bio, Inc. (GOSS)
As-reported financials and recent SEC filings for Gossamer Bio, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$48.5M
Net income
$-170.4M
Net margin
—
Diluted EPS
$-0.75
ROE
138.8%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $48.5M | $114.7M | $0 | $0 | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-170.7M | $-59.9M | $-183.8M | $-218.6M | $-216.1M |
| Net income | $-170.4M | $-56.5M | $-179.8M | $-229.4M | $-234.0M |
| Diluted EPS | $-0.75 | $-0.25 | $-1.18 | $-2.71 | $-3.13 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-01
View on EDGAR →SCHEDULE 13D/A2026-07-01
View on EDGAR →8-K2026-06-17
View on EDGAR →SCHEDULE 13G2026-06-11
View on EDGAR →SCHEDULE 13D2026-06-11
View on EDGAR →SCHEDULE 13G2026-06-11
View on EDGAR →DEF 14A2026-06-09
View on EDGAR →SCHEDULE 13G2026-06-09
View on EDGAR →Largest Healthcare peers
Go deeper on GOSS
Search Gossamer Bio, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.